Company: AGIO
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0001193125-25-096719
Chunk: 158

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 158
---
 upon such true and lawful attorneys to vote in their discretion on such other matters as may properly come before the meeting and revoking any proxy heretofore given. THE SHARES REPRESENTED BY THIS PROXY WILL BE VOTED AS DIRECTED OR, IF NO DIRECTION IS GIVEN, SHARES WILL BE VOTED IDENTICAL TO THE BOARD OF DIRECTORS’ RECOMMENDATION.This proxy, when properly executed, will be voted in the manner directed herein. In their discretion, the Named Proxies are authorized to vote upon such other matters that may properly come before the meeting or any adjournment or postponement thereof. You are encouraged to specify your choice by marking the appropriate box (SEE REVERSE SIDE) but you need not mark any box if you wish to vote in accordance with the Board of Directors’ recommendation. The Named Proxies cannot vote your shares unless you sign (on the reverse side) and return this card. PLEASE BE SURE TO SIGN AND DATE THIS PROXY CARD AND MARK ON THE REVERSE SIDE Copyright ©2025 BetaNXT, Inc. or its affiliates. All Rights Reserved

| Agios Pharmaceuticals, Inc. Annual Meeting of Stockholders |

| Please make your marks like this: |

THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOREACH OF THE NOMINEES LISTED IN PROPOSAL 1 AND FORPROPOSALS 2, 3 AND 4.

|    |     | PROPOSAL                                                                                                                                                                                                                                                |     |     |     | YOUR VOTE |     |         |     | BOARD OF   
 DIRECTORS  
 RECOMMENDS |
| 1. |     | To elect each of the two Class III director nominees set forth in the Proxy Statement, each to serve for a three-year term expiring at the 2028 annual meeting of stockholders and until his or her respective successor is duly elected and qualified. |     |     |     |           |     |         |     |            |
|    |     |                                                                                                                                                                                                                                                         |     | FOR |     | WITHHOLD  |     |         |     |            |
|    |     | 1.01 Jacqualyn A. Fouse, Ph.D.                                                                                                                                                                                                                          |     | ☐   |     | ☐         |     |         |     | FOR        |
|    |     | 1.02 David Scadden, M.D.                                                                                                                                                                                                                                |     | ☐   |     | ☐         |     |         |     |